Gilead’s Kite Signs US$1.64 B In Vivo CAR-T Deal with Pregene Biopharma
By Shikha Kashyap
Pharma Deals Review: Vol 2025 Issue 11 (Table of Contents)
Published: 5 Nov-2025
DOI: 10.3833/pdr.v2025.i11.2982 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In a contrast to its peers, Gilead Sciences’ Kite Pharma has signed an exclusive license agreement with China’s Pregene Biopharma to co-develop next-generation in vivo CAR-T therapies...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS